Loading...
Market
How will Amgen's stock price respond to MariTide Phase 2 results by end of 2024?
2
Resolution / Starting Odds
Stock price increases by more than 10% • 25%
Stock price remains within +/- 10% range • 25%
Stock price decreases by more than 10% • 25%
Stock price fluctuates but ends within +/- 5% range • 25%
Stock market data and financial news analysis
Story
Amgen's MariTide Achieves 20% Weight Loss in Phase 2; Shares Drop 12%
Nov 26, 2024, 12:20 PM
Amgen Inc. announced that its experimental obesity drug, MariTide (maridebart cafraglutide), a GLP-1/GIPR agonist, demonstrated up to 20% average weight loss at 52 weeks in a Phase 2 study involving people with obesity or overweight. In patients with Type 2 diabetes, the drug achieved approximately 17% weight loss and lowered HbA1c levels by 2.2 points. The study showed no weight-loss plateau and reported a gastrointestinal dropout rate of less than 8%. Amgen scheduled a conference call at 8 am ET to discuss the data. Despite the promising results, Amgen's stock price fell by up to 12% in premarket trading, indicating that the data may have fallen short of market expectations.
View original story
Similar markets
Exceeds forecasts • 25%
Meets forecasts • 25%
Below forecasts • 25%
Significantly below forecasts • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Yes • 50%
No • 50%
Less than 5% increase • 25%
5% to 10% increase • 25%
10% to 15% increase • 25%
More than 15% increase • 25%
Yes • 50%
No • 50%
Sarepta stock up >10% • 25%
Arrowhead stock up >10% • 25%
Both stocks up >10% • 25%
Neither stock up >10% • 25%